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Abstract
Objective. We conducted a study to examine recent trends in population-based utilization rates for liver resection surgery in
England, to help identify potentially unmet healthcare need and to help inform future service planning. Materials and
methods. Hospital Episodes Statistics data were analysed for the 5-year period 20001 to 20045 to identify episodes of care
relating to liver resection surgery (defined as OPSC IV codes J21 to J24, J31, J38 and J39). Results. In England, the liver
excision surgery population access rate was 1.82 and 2.95/100 000 general population in 20001 and 20045, respectively
 a 62% increase during the 5-year study period, or a mean 12% annual increase. About two-thirds of all liver resection
surgery (69%) related to metastatic liver disease. Between English regions, utilization rates ranged from 0.5 to 4.5/100 000
general population in 20001; and from 0.8 to 4.6/100 000 general population in 20045. Discussion. In recent years, a
rapid increase in liver resection surgery activity has been observed. Most of the activity was related to metastatic disease.
There was substantial regional variation in population utilization rates within the same country. This variation is unlikely to
represent regional differences in disease burden and healthcare need.
Introduction
Liver resection surgery has historically had a narrow
spectrum of indications. Increasingly over recent
years, evidence suggests that liver resection surgery
could be an effective intervention for certain patients
suffering from metastatic liver disease. This is parti-
cularly true for colorectal liver metastases, where 5-
year survival rates of between 30% and 47% have
been reported [14]. In this respect, metastatic liver
disease is rather unique among common presentations
of malignant disease, as among surgically treatable
patients it has cure rates that exceed those observed in
many other primary cancers of solid organs (e.g.
oesophageal or pancreatic cancers).
Further advances in operative and haemostatic
techniques over recent years are believed to have
made liver resection surgery both safer and more
effective, and may have increased the proportion of
patients for whom surgical resection is possible by up
to 20% [5]. Preoperative portal vein embolization,
two-stage hepatectomy (i.e. resection of different
affected parts of the liver during more than one
operation) and administration of preoperative
‘down-staging’ chemotherapy, may have also rendered
operable a patient subgroup previously thought to be
ineligible for surgery [57]. Conversely, advances in
imaging techniques (e.g. positron emission tomogra-
phy (PET) and PET-CT imaging) may have dimin-
ished the ‘pool’ of potentially eligible patients,
because of better detection of previously undetectable
disseminated disease, or may do so in the future.
Therefore, there is currently some uncertainty about
the percentage of patients presenting with metastatic
liver disease who have surgically treatable illness.
Liver surgery is dependent on the availability of
relevant surgical expertise, which has historically been
limited. It could therefore be postulated that diffusion
of liver resection surgery might have been slow, and
that provision of this type of surgery may have been
below the healthcare need levels that could be
theoretically expected. A previous study from an
English liver surgery unit has indicated a theoretical
healthcare need of approximately 3.9 liver resection
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surgery episodes for metastatic disease of the liver
from colorectal primaries per 100 000 general popula-
tion [8]. However, this evidence relates to only one
study and research setting and to metastatic liver
disease from colorectal primaries alone, i.e. excluding
other potentially important indications, such as meta-
static disease from other primary sites and primary
liver neoplasms. We therefore conducted a survey
using routine data to examine historical and recent
utilization levels, comparing them to theoretically
expected healthcare need, and to examine whether
there was variation over time in population access
rates by region.
Materials and methods
Hospital Episodes Statistics (HES) data were ana-
lysed for the period 20001 to 20045 to identify
episodes of care relating to liver resection surgery
(defined as episodes of care with OPSC IV codes J21
to J24, J31, J38 and J39 in the primary procedure
position). The HES dataset contains information
about clinical episodes of care that take place in
English hospitals of the National Health Service
(NHS) [9]. For relevant episodes of care as defined
above, the following information was also obtained:
regional office of patient residence, age, sex and
diagnosis (defined as the International Classifications
of Diseases-10 diagnostic code in the primary diag-
nosis field). Office for National Statistics data were
used in the denominators, for calculation of general
population access rates. Descriptive analysis was
subsequently undertaken.
Results
Among residents in England who were treated in
NHS hospitals, there were overall 896 care episodes
relating to liver resection surgery in 20001, increas-
ing to 1451 such episodes in 20045. For the whole
of England, the population access rate for liver
excision surgery increased from 1.82/100 000 general
population in 20001 to 2.23, 2.33, 2.83 and 2.95/
100 000 general population in the years 20012,
20023, 20034 and 20045, respectively (Table I).
This represents a 62.09% increase during the 5-year
study period (20045 over 20001), or a mean
12.42% annual increase, for each year of the study
period.
Of all liver excision surgery episodes during the
study period, 55.51% were in men, and 44.46% in
women. The mean age of patients treated with liver
resection was 57.18, 57.56, 59.19, 59.10 and 59.27
years for the years 20001 to 20045, respectively.
Of all liver excision surgery episodes during the
study period, 68.68% had a diagnosis of metastatic
disease (Table II); 11.55% had a diagnosis of primary
liver cancer; 4.80% had a diagnosis of either a benign
neoplasm or a neoplasm of uncertain or unknown T
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behaviour; 1.15% had a diagnosis of congenital
malformations of the hepatobiliary system; 0.89%
had a diagnosis of traumatic injury and 12.92% had
other diagnoses.
There was considerable variation in population
rates of liver resection surgery per 100 000 general
population between different English regions during
the study period (Figure 1 and Table I). Rate ratios
between the highest and lowest (in terms of utilization
rates) English regions were 8.6 (absolute rate range
0.54.5/100 000 general population) in 20001 and
5.9 in 20045 (absolute rate range0.84.6/100 000
general population).
Discussion
In England and during a recent time period, evidence
of a relatively rapid increase in liver resection surgery
activity has been observed. There was little change in
the mean age of operated patients. About two-thirds
Table II. Breakdown and proportion (in relation to all procedures) of metastatic liver disease coded diagnosis among patients treated with
liver resection surgery, 20001 to 20045.
ICD-10 code Description of code Number of episodes %*
C78 Secondary malignant neoplasm of respiratory and digestive organs 3698 61.83
C18 Malignant neoplasm of colon 117 1.96
C23 Malignant neoplasm of gallbladder 65 1.09
C19 Malignant neoplasm of rectosigmoid junction 60 1.00
C20 Malignant neoplasm of rectum 40 0.67
C80 Malignant neoplasm without specification of site 20 0.33
C25 Malignant neoplasm of pancreas 15 0.25
C16 Malignant neoplasm of stomach 13 0.22
C26 Malignant neoplasm of other and ill-defined digestive organs 12 0.20
C64 Malignant neoplasm of kidney, except renal pelvis 13 0.22
C74 Malignant neoplasm of adrenal gland 8 0.13
C17 Malignant neoplasm of small intestine 7 0.12
C79 Secondary malignant neoplasm of other sites 7 0.12
C49 Malignant neoplasm of other connective and soft tissue 5 0.08
C15 Malignant neoplasm of oesophagus 4 0.07
C56 Malignant neoplasm of ovary 4 0.07
C77 Secondary and unspecified malignant neoplasm of lymph node 5 0.09
C48 Malignant neoplasm of retroperitoneum and peritoneum 3 0.05
C67 Malignant neoplasm of bladder 2 0.03
D01 Carcinoma in situ of other and unspecified digestive organs 2 0.03
C08 Malignant neoplasm of other and unspecified major salivary glands 1 0.02
C34 Malignant neoplasm of bronchus and lung 1 0.02
C43 Malignant melanoma of skin 1 0.02
C45 Mesothelioma 1 0.02
C61 Malignant neoplasm of prostate 1 0.02
C66 Malignant neoplasm of ureter 1 0.02
C68 Malignant neoplasm of other and unspecified urinary organ 1 0.02
D03 Melanoma in situ 1 0.02
ICD-10, International Classification of Diseases-10.
*In relation to all procedures, whatever the ICD-10 diagnosis.
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Figure 1. Rate of liver excision surgery (100 000 general population) by English region and year (20001 and 20045).
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of all activity was related to metastatic disease of the
liver, and about four-fifths of all activity was related to
cancer (secondary or primary). Substantial regional
differences in population access rates to liver surgery
activity were observed, and persisted during the study
period.
About two-thirds of liver resection surgery activity
related to metastatic liver disease. The nature and
source of the data used (HES dataset) make it
impossible to have a precise estimate of the proportion
of such activity relating to metastatic disease from
colorectal cancer primaries. However, even if one
assumes that all metastatic liver disease presentations
among patients treated with liver resection surgery did
relate to metastatic disease from colorectal primaries,
this would have meant that the liver resection activity
actually observed for colorectal liver metastases was
about half the previously theoretically predicted
population rate levels, i.e. 3.9/100 0000 [8].
A considerable degree of variation in relation to
population-based utilization rates was observed be-
tween the populations of different English regions.
Given this many-fold variation, this is very unlikely to
be associated with regional differences in disease
burden. Therefore, it most likely reflects differences
either in care pathways and clinical management
practices (e.g. primary and secondary care physicians
not always either choosing or being able to refer
patients to liver surgery centres) and/or differences in
relation to capacity and availability of surgical ex-
pertise. However, it is impossible to answer this
question with empirical evidence, given the retro-
spective nature of this study and the data available.
Nevertheless, given that the variation in utilization
rates is unlikely to represent differences in disease
burden, this inequitable distribution should inform
and be addressed by future policy initiatives.
Using HES, we calculated that during the same
study period (20001 to 20045), about 1000
pancreatic excision surgery procedures were carried
out annually in the UK (data not shown). This means
that the volume of liver resection surgery currently
exceeds that of pancreatic excision surgery. Pancreatic
and liver surgery are usually, but not always, served by
the same surgical subspecialty. Pancreatic surgery in
the UK has undergone a great degree of centralization
to tertiary centres over recent years, following the
2001 Improving Outcomes Guidance for Upper
Gastrointestinal Cancers [10]. This important policy
document did not include any reference to liver
surgery, which therefore remains bereft of any author-
itative national or professional guidance about the
appropriate minimum annual activity and population
catchment size for each centre, in order to both
quality assure outcomes and to optimize the cost-
effectiveness of services. Recent guidelines have not
stipulated such requirements to the level of detail
required for service planning [11]. We argue that a
national policy for appropriate designation of liver
surgery services is necessary to help best accommo-
date the recent and potential future growth in
healthcare need for this potentially life-saving surgical
intervention.
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